Published in Prog Neuropsychopharmacol Biol Psychiatry on April 10, 2012
Hub and switches: endocannabinoid signalling in midbrain dopamine neurons. Philos Trans R Soc Lond B Biol Sci (2012) 0.89
Modulation of the endocannabinoid system: vulnerability factor and new treatment target for stimulant addiction. Front Psychiatry (2013) 0.88
Analysis of ECs and related compounds in plasma: artifactual isomerization and ex vivo enzymatic generation of 2-MGs. J Lipid Res (2014) 0.86
Peripheral endocannabinoid system dysregulation in first-episode psychosis. Neuropsychopharmacology (2013) 0.81
Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research. Front Pharmacol (2017) 0.75
Parkinson's disease: mechanisms and models. Neuron (2003) 14.84
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature (1996) 8.99
The molecular logic of endocannabinoid signalling. Nat Rev Neurosci (2003) 7.78
The endogenous cannabinoid system controls extinction of aversive memories. Nature (2002) 7.19
Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature (2001) 6.12
Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci (1991) 5.88
Role of endogenous cannabinoids in synaptic signaling. Physiol Rev (2003) 5.70
Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A (2002) 5.33
Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol (2008) 5.32
CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science (2003) 5.22
Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature (2007) 4.36
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol (2007) 4.22
Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron (2001) 4.15
An endocannabinoid mechanism for stress-induced analgesia. Nature (2005) 4.03
The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology (1999) 3.78
Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science (2011) 3.48
Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci (1999) 3.45
Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat Neurosci (2002) 3.34
An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature (2001) 3.33
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci (2003) 3.25
An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A (2002) 3.16
Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci (2010) 3.11
Transient receptor potential channels: targeting pain at the source. Nat Rev Drug Discov (2009) 2.88
Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci (2008) 2.87
Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience (2004) 2.84
Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron (2001) 2.81
Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci U S A (2003) 2.74
The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci (2010) 2.37
Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J Neurosci (2007) 2.32
Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci (2005) 2.31
Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci (1997) 2.25
The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J Biol Chem (2001) 2.13
Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci (2004) 2.10
Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol (2003) 2.09
Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway. J Biol Chem (2006) 2.09
Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience (1992) 2.06
Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol (1997) 2.05
Evidence for novel cannabinoid receptors. Pharmacol Ther (2005) 2.00
Animal models of neurological deficits: how relevant is the rat? Nat Rev Neurosci (2002) 1.96
Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci (2005) 1.92
Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann N Y Acad Sci (2003) 1.92
Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem (2009) 1.91
Endocannabinoid-dependent plasticity at GABAergic and glutamatergic synapses in the striatum is regulated by synaptic activity. Eur J Neurosci (2009) 1.88
2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A (2001) 1.86
Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions. Mol Pharmacol (2005) 1.86
Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. Exp Neurol (2007) 1.85
Endocannabinoid-mediated long-term plasticity requires cAMP/PKA signaling and RIM1alpha. Neuron (2007) 1.81
Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system. Mol Pharmacol (2010) 1.81
Are cannabinoids endogenous ligands for the VR1 capsaicin receptor? Trends Pharmacol Sci (2000) 1.80
Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci U S A (2003) 1.76
The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol (2007) 1.74
Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology (2004) 1.73
Identification of a novel endocannabinoid-hydrolyzing enzyme expressed by microglial cells. J Neurosci (2007) 1.71
Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res (1999) 1.68
Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Mol Pharmacol (2005) 1.66
Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci U S A (2004) 1.66
Cellular accumulation of anandamide: consensus and controversy. Br J Pharmacol (2003) 1.66
Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry (2008) 1.64
Biochemistry and pharmacology of endovanilloids. Pharmacol Ther (2007) 1.64
Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci (2001) 1.63
A second fatty acid amide hydrolase with variable distribution among placental mammals. J Biol Chem (2006) 1.63
CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol (2001) 1.63
Cannabinoids and neuroinflammation. Br J Pharmacol (2004) 1.62
Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem (2002) 1.61
Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem (2009) 1.60
Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci (1999) 1.59
Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology (2007) 1.59
Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex. Neuropsychopharmacology (2011) 1.57
Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience (2001) 1.57
Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol Pharmacol (2005) 1.55
Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology (2004) 1.55
N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J (2000) 1.55
Novel cannabinoid receptors. Br J Pharmacol (2007) 1.55
Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain (2009) 1.50
Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther (2002) 1.43
WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur J Neurosci (2009) 1.42
Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. J Neurosci (2003) 1.41
Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci (2002) 1.40
Elevated endogenous cannabinoids in schizophrenia. Neuroreport (1999) 1.38
The role of glial cells in Parkinson's disease. Curr Opin Neurol (2001) 1.36
Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. Neuroreport (2000) 1.36
Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. J Neurochem (2006) 1.35
Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. Br J Pharmacol (2007) 1.32
Unawareness of dyskinesias in Parkinson's and Huntington's diseases. Neurol Sci (2001) 1.32
Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J (2000) 1.32
Alterations of endocannabinoid signaling, synaptic plasticity, learning, and memory in monoacylglycerol lipase knock-out mice. J Neurosci (2011) 1.32
Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors. J Neurosci (2008) 1.32
Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. J Neurosci (2000) 1.31
Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2004) 1.30
Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis (2003) 1.29
Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J Neurosci (2005) 1.26
Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometry. J Lipid Res (2004) 1.25
Receptors for acylethanolamides-GPR55 and GPR119. Prostaglandins Other Lipid Mediat (2009) 1.23
Parkinson's disease: levodopa-induced dyskinesia and signal transduction. FEBS J (2008) 1.22
Targeting dopamine D2 and cannabinoid-1 (CB1) receptors in rat nucleus accumbens. J Comp Neurol (2006) 1.22
The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. Cell Mol Life Sci (2006) 1.22
Evolutionary origins of the endocannabinoid system. Gene (2006) 1.21
Cannabinoids and prefrontal cortical function: insights from preclinical studies. Neurosci Biobehav Rev (2006) 1.21
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis (2005) 1.19
WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur J Neurosci (2009) 1.42
Wired to run: exercise-induced endocannabinoid signaling in humans and cursorial mammals with implications for the 'runner's high'. J Exp Biol (2012) 1.05
Exercise-induced endocannabinoid signaling is modulated by intensity. Eur J Appl Physiol (2012) 0.94
Acetaminophen differentially enhances social behavior and cortical cannabinoid levels in inbred mice. Prog Neuropsychopharmacol Biol Psychiatry (2012) 0.87
Contribution of corticosterone to cued versus contextual fear in rats. Behav Brain Res (2007) 0.80